COMMUNIQUÉS West-GlobeNewswire

European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
07/07/2026
Phased review by EMA aims to accelerate assessment of company's investigational drug daraxonrasib in pancreatic cancer based on unprecedented clinical results from pivotal Phase 3 RASolute 302 trial Rolling submission [...]
Carbonium Core CEO Details Strategy to Supply Critical Material Powering the AI-Driven Nuclear Renaissance
07/07/2026
Management outlines commercialization roadmap toward a potential $1.5 billion annual revenue opportunity as the Company seeks to build America's first commercial-scale domestic supply chain for nuclear-grade graphite [...]
Clinical Excellence in Continuity of Care: Counterpart Assistant (CA) Use Associated With Stronger Performance Across Transitions of Care Measures and Post-Hospitalization Follow-Up
07/07/2026
CA-enabled PCPs showed better HEDIS® post-acute performance, including 33% higher discharge information receipt and an 11% higher rate of post-discharge medication reconciliation, underscoring the role of AI-enabled [...]
Alamar Biosciences Launches the First Multiplexed Blood-based Immunoassay for eMTBR-Tau, One of the Most Important Biomarkers in Alzheimer’s Disease Research
07/07/2026
eMTBR-Tau offers a non-invasive, blood-based measurement of the tau tangle burden, the core pathology associated with disease progression and cognitive decline in Alzheimer’s disease Immunoassay for eMTBR-Tau is [...]
Privia Health to Report Second Quarter 2026 Results on Thursday, August 6
07/07/2026
ARLINGTON, Va., July 07, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its second-quarter and six-month periods ended June 30, 2026 [...]
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling
07/07/2026
Company also advances U.S. regulatory pathway for ONP-002 with FDA Type B meeting request All three Australian Phase IIa trial sites — Mackay Base Hospital, Alfred Health, and Royal Adelaide Hospital — are now active [...]
Oncotelic Successfully Completes Initial Safety Cohort of Phase 1b SP-03-B101 Trial; Independent Safety Review Committee Recommends Dose Escalation and European Expansion Underway
07/07/2026
Clinical Program Advances Following Favorable Safety Review; Peer-Reviewed Publication Further Validates Deciparticle ™ Platform SAN DIEGO, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- Oncotelic (OTCQB:OTLC), an AI/Robotic [...]
Eupraxia Pharmaceuticals Strengthens Board with Three Industry Leaders in Drug Development and Commercialization
07/07/2026
VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary [...]
PDV MedTech and Corscience Announce Strategic Partnership to Advance MedTech Development and Manufacturing Across the US and Europe
07/07/2026
Collaboration connects European development expertise with U.S. manufacturing to give medtech innovators a seamless path from concept to commercialization for safety-critical medical devices. MORGAN HILL, Calif. and [...]
PDV MedTech et Corscience annoncent un partenariat stratégique visant à faire progresser le développement et la fabrication de technologies médicales aux États-Unis et en Europe
07/07/2026
Cette collaboration associe l’expertise européenne en développement aux capacités de fabrication américaines afin d’offrir aux innovateurs du secteur des technologies médicales un parcours fluide, de la conception à la [...]
Nu-Tek BioSciences présente ses innovations en matière de nutriments cellulaires et son expertise en matières premières lors de la conférence SIMB 2026
07/07/2026
Nu-Tek présentera des données démontrant comment ses nutriments pour milieux de culture sans composants d’origine animale améliorent le rendement, optimisent les procédés et renforcent la sécurité d’approvisionnement [...]
Press Release Biocartis NV: Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics
07/07/2026
PRESS RELEASE, July 07, 2026 – 08:00 CDT Biocartis and Discovery Life Sciences Announce Strategic Collaboration to Advance Precision Oncology Diagnostics ITASCA, IL, US and HUNTSVILLE, AL, US – July 07, 2026. Today, [...]
Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation
07/07/2026
Realbotix Robots and AI to Deploy in Evidence-Based Pilot Designed to Improve Wellbeing and Address Loneliness Among Older Adults in UK Care Settings; Realbotix Becomes Accredited Supplier on Bloom’s Public Sector [...]
A $190 Billion Weight-Loss Boom Has Exposed a Tissue-Restoration Gap Today’s Injectables Were Not Built to Fill
07/07/2026
Conexeu Completes 12-Month Preclinical P.R.O.O.F Study, Supporting Its Intended Move Into the $11 Billion Medical Aesthetics Market as a Platform¹ Study Highlights P.R.O.O.F study complete, marking an important catalyst [...]
OKYO Pharma to Participate in a Fireside Chat at Piper Sandler 2026 Virtual Ophthalmology Symposium
07/07/2026
LONDON and NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO ), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain ( [...]
ImageneBio Appoints Matt Robbins as General Counsel
07/07/2026
Brings more than 15 years of corporate, securities, and transactional experience advising public and private life sciences companies SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene” [...]
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
07/07/2026
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company [...]
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease
07/07/2026
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track: symptomatic data readout - Q1 2027, disease-modifying data readout - Q1 2028 Company positions for two NDA [...]
U.S. FDA Grants Priority Review to Agios’ sNDA for Mitapivat in Sickle Cell Disease
07/07/2026
FDA’s PDUFA goal date is November 1, 2026 If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease CAMBRIDGE, Mass., July 07, 2026 (GLOBE NEWSWIRE) -- Agios [...]

Pages